MAO x H1 receptor

This will be a phase 2a single-center, randomized, blinded, vehicle-controlled exploratory study to assess the activity and safety of CRx-197 in subjects with plaque psoriasis. Approximately 20 male or female subjects with chronic plaque type psoriasis, 18 to 70 years of age, will be included in this study.
All subjects with stable psoriatic plaques will receive all of the following treatments each in a separate test field, once each day for four weeks under occlusion:
CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
0.1% nortriptyline HCl topical cream
0.005% calcipotriol topical cream
Vehicle of CRx-197 topical cream (placebo)

This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free vehicle cream of CRx-197)in healthy volunteers.